BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33825093)

  • 1. [Histological subtypes of renal cell carcinoma : Overview and new developments].
    Polifka I; Agaimy A; Moch H; Hartmann A
    Pathologe; 2021 May; 42(3):294-304. PubMed ID: 33825093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic kidney cancer syndromes.
    Ho TH; Jonasch E
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1347-55. PubMed ID: 25190700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
    Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
    Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
    Maher ER
    World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of different renal cell carcinoma entities].
    Rupp NJ; Moch H
    Urologe A; 2020 Feb; 59(2):135-141. PubMed ID: 31974661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
    Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
    Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Entities in Renal Neoplasia.
    Mehra R; Smith SC; Divatia M; Amin MB
    Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Hereditary Renal Cell Cancer.
    Menko FH; Maher ER
    Recent Results Cancer Res; 2016; 205():85-104. PubMed ID: 27075350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the hereditary background of renal cancer in Denmark.
    Christensen MB; Wadt K; Jensen UB; Lautrup CK; Bojesen A; Krogh LN; Overeem Hansen TV; Gerdes AM
    PLoS One; 2019; 14(4):e0215725. PubMed ID: 31034483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma.
    Freifeld Y; Ananthakrishnan L; Margulis V
    Curr Urol Rep; 2018 Aug; 19(10):82. PubMed ID: 30116909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving classification of renal cell neoplasia.
    Delahunt B; Srigley JR
    Semin Diagn Pathol; 2015 Mar; 32(2):90-102. PubMed ID: 25753529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic syndromes associated with renal cell carcinoma: a review.
    Azeem K; Kollarova H; Horakova D; Magnuskova S; Janout V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):231-8. PubMed ID: 22286808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hereditary kidney cancers: The pathologist's view in 2020].
    Verkarre V; Morini A; Denize T; Ferlicot S; Richard S
    Ann Pathol; 2020 Apr; 40(2):148-167. PubMed ID: 32197858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary kidney cancer: unique opportunity for disease-based therapy.
    Linehan WM; Pinto PA; Bratslavsky G; Pfaffenroth E; Merino M; Vocke CD; Toro JR; Bottaro D; Neckers L; Schmidt LS; Srinivasan R
    Cancer; 2009 May; 115(10 Suppl):2252-61. PubMed ID: 19402075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics of familial renal cell carcinoma syndromes.
    Cohen D; Zhou M
    Clin Lab Med; 2005 Jun; 25(2):259-77. PubMed ID: 15848736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 20. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
    Rupp N; Moch H
    Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.